| Grant ID | RP100348 |
| Awarded On | January 20, 2010 |
| Title | Development of small molecule inhibitors that target the oncogenic SRC-3 coactivator and their characterization as novel anti-cancer agents |
| Program | Academic Research |
| Award Mechanism | Individual Investigator |
| Institution/Organization | Baylor College of Medicine |
| Principal Investigator/Program Director | Bert O'Malley |
| Cancer Sites | Breast, Colorectal, Lung and Bronchus, Multiple Sites, Ovary, Pancreas, Prostate |
| Contracted Amount | $789,473 |
| Lay Summary |
A group of proteins called coactivators are frequently overexpressed and ‘oncogenic’ in multiple human cancers; the most prominent of these is steroid receptor coactivator-3/amplified in breast cancer 1 (SRC-3/AIB1), a molecule studied extensively in our lab (>40 publications). Overexpression of SRC-3 has been validated as an oncogene in breast, ovarian, prostate, pancreatic, lung, and colorectal cancers; it is estimated to be involved in 322,000 new cancer cases and 91,000 cancer deaths every year. Given the fact that SRC-3-dependent cancers are frequently resistant to established chemotherapeutics, the development of small molecule inhibitors (SMIs) to inhibit SRC-3 function is critically... |